Stock exchanges & markets

Overview Watchlists

Galderma wins China approval for Relfydess to treat frown lines

(AWP Alliance News) - China's National Medical Products Administration approved Galderma's Relfydess for temporary improvement of moderate-to-severe frown lines in adults. The ready-to-use liquid neuromodulator is already authorized in more than 35 markets worldwide.

https://www.publicnow.com/view/BE6DFD8C05256F5AFE04F7225282271E98941431…

Disclaimer: This news brief was created using generative artificial intelligence. Galderma Group AG published the original content used to generate this news brief on October 23, 2026, and is solely responsible for the information contained therein.

Learn more about our offers

  • Keep a close eye on your favourite shares

    Watchlist

    Don’t miss out on share price trends. Track your favourite shares (CH, EU & US) in real time with customised watchlists.

    Sign up now

  • Compare ETFs systematically

    ETF Compass

    Find the products that suit your investment goals.

    Try the ETF Compass

  • How to find the best shares

    theScreener

    Search through around 6,500 securities using criteria such as opportunities and risks or expected dividend yield.

    Test now